本頁面由Tiger Trade Technology Pte. Ltd.提供服務

BridgeBio Pharma, Inc.

68.39
-3.9900-5.51%
盤後68.600.2100+0.31%19:30 EDT
成交量:399.30萬
成交額:2.75億
市值:133.91億
市盈率:-19.16
高:72.41
開:72.26
低:66.96
收:72.38
52周最高:93.42
52周最低:48.78
股本:1.96億
流通股本:1.67億
量比:1.80
換手率:2.39%
股息:- -
股息率:- -
每股收益(TTM):-3.5686
每股收益(LYR):-3.7850
淨資產收益率:-1789.67%
總資產收益率:-26.00%
市淨率:-5.32
市盈率(LYR):-18.07

資料載入中...

2025/01/31

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/01/28

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/01/28

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/01/13

重要事件披露

Form 8-K - Current report
2024/11/25

重要事件披露

Form 8-K - Current report
2024/11/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/11/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/11/12

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/11/12

重要事件披露

Form 8-K - Current report
2024/11/06

超過5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/09/17

超過5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/09/13

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/09/11

重要事件披露

Form 8-K - Current report
2024/08/21

重要事件披露

Form 8-K - Current report
2024/08/20

超過5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/08/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/01

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/08/01

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/08/01

重要事件披露

Form 8-K - Current report